Pembrolizumab
3475-02C
Phase 2 mab completed
Quick answer
Pembrolizumab for Melanoma is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Melanoma
- Phase
- Phase 2
- Modality
- mab
- Status
- completed